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Abstract: Intracellular signaling through the T cell receptor (TCR) is essential for T cell development
and function. Proper TCR signaling requires the sequential activities of Lck and ZAP-70 kinases,
which result in the phosphorylation of tyrosine residues located in the CD3 ITAMs and the LAT
adaptor, respectively. LAT, linker for the activation of T cells, is a transmembrane adaptor protein
that acts as a scaffold coupling the early signals coming from the TCR with downstream signaling
pathways leading to cellular responses. The leukemic T cell line Jurkat and its derivative mutants
J.CaM1.6 (Lck deficient) and J.CaM2 (LAT deficient) have been widely used to study the first signaling
events upon TCR triggering. In this work, we describe the loss of LAT adaptor expression found in a
subline of J.CaM1.6 cells and analyze cis-elements responsible for the LAT expression defect. This
new cell subline, which we have called J.CaM1.7, can re-express LAT adaptor after Protein Kinase C
(PKC) activation, which suggests that activation-induced LAT expression is not affected in this new
cell subline. Contrary to J.CaM1.6 cells, re-expression of Lck in J.CaM1.7 cells was not sufficient to
recover TCR-associated signals, and both LAT and Lck had to be introduced to recover activatory
intracellular signals triggered after CD3 crosslinking. Overall, our work shows that the new LAT
negative J.CaM1.7 cell subline could represent a new model to study the functions of the tyrosine
kinase Lck and the LAT adaptor in TCR signaling, and their mutual interaction, which seems to
constitute an essential early signaling event associated with the TCR/CD3 complex.
Keywords: Lck; LAT; J.CaM1.6; TCR; signaling
1. Introduction
The activation of T lymphocytes constitutes a central event in adaptive immune
responses against infectious pathogens or tumor cells. T lymphocytes recognize threatening
foreign or tumoral antigens in the form of peptides bound to major histocompatibility
complex molecules (pMHC). To do so, T cells express at their surface the T cell receptor
(TCR) heterodimer, composed of TCR-α and TCR-β or TCR-γ and TCR-δ subunits, which,
upon binding with their cognate antigens, trigger signaling cascades through the TCR
associated CD3 subunits [1–3]. After activation, T lymphocytes undergo clonal expansion
and differentiation into various types of effector T cells, which in turn contribute in different
ways to the elimination of antigen and the establishment of immune memory. In humans,
defects in the development of T cells usually result in the early occurrence of severe
infections, revealing the essential role of this cell population for acquired immunity [4].
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Most T lymphocytes express TCR-αβ heterodimers which associate with four trans-
membrane polypeptide subunits, namely, CD3-δ, -γ, -ε, and -ζ [1,2,5]. The TCR engagement
by pMHC complexes expressed at the surface of antigen-presenting cells (APCs) triggers
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) located
in the cytosolic domains of CD3 subunits by the p56lck tyrosine kinase (Lck). This in
turn recruits ZAP-70 tyrosine-kinase to the cell membrane. Once there, ZAP-70 is also
phosphorylated and enzymatically activated by Lck, leading to the subsequent tyrosine
phosphorylation of several intracellular substrates, including the LAT (Linker for the
Activation of T cells) transmembrane adaptor.
LAT is an integral transmembrane adaptor protein of 36–38 kDa expressed in thymo-
cytes, peripheral T lymphocytes, natural killer (NK) cells, mast cells, platelets, and pre-B
cells [6,7]. Most of the functions of LAT are carried out by its four conserved carboxy-
terminal tyrosines, which upon phosphorylation create docking sites for several cytosolic
signaling effectors [6,8–10]. Many studies have established the crucial role of LAT in TCR
signaling, showing that phosphorylation of LAT tyrosines constitutes nucleation sites for
adapters and important signaling complexes that together mediate T cell activation [11,12].
One of the proteins binding to phosphorylated LAT is the adaptor Gads [13,14]. Gads
is a small cytosolic adaptor composed of one SH2 and two SH3 domains and is consti-
tutively bound via its carboxy-terminal SH3 domain to a proline-rich region in another
cytosolic adaptor, SLP-76. Together they associate with phosphorylated LAT. Once this
complex has been formed, PLC-γ1 interacts with SLP-76 via its SH3 domain [15]. PLC-γ1
is in turn phosphorylated and activated by Itk kinase, resulting in phospholipase acti-
vation [16,17]. Activated PLC-γ1 then hydrolyzes PIP2 to produce IP3 and DAG, with
concomitant generation of Ca2+ flux and Erk activation [5]. Therefore, LAT coordinates the
assembly of a multiprotein signaling complex referred to as “LAT signalosome”, which
links the TCR to the main intracellular signaling pathways that regulate T cell development
and activation [18].
It is widely accepted that in T cells LAT is phosphorylated by activated ZAP-70 tyro-
sine kinase [6,10]. However, the first report about LAT function in T cells showed, through
cotransfection experiments of 293T cells with a constitutively active form of Lck and LAT,
that weak phosphorylation of LAT by Lck was possible [6]. More recently it has been
shown that although ZAP-70 is the main kinase phosphorylating LAT tyrosine residues,
Lck can weakly phosphorylate several LAT tyrosine residues [19,20]. The relationship
between Lck kinase and LAT adaptor is still controversial, and some reports favor a role
for both molecules in positive feedback loops [21,22]. However, other groups have found
evidence to support the fact that LAT and Lck interaction has a negative regulatory effect
on TCR signaling [23–25].
Much of the knowledge acquired about TCR signaling came from studies carried
out with transformed T cell lines, and one of the best known of these model systems is
the Jurkat leukemic T cell line [26]. The use of Jurkat cells has been critical for seminal
contributions to the field of T cell biology, such as the finding that TCR ligation triggers
intracellular Ca2+ mobilization [27], that cell surface expression of the TCR-αβ heterodimer
requires co-expression of CD3 polypeptides [28], that TCR ligation activates PLC-γ1 [29], or
the observation that TCR stimulation triggers protein tyrosine phosphorylation [30,31]. Of
note, utilizing a combined selection protocol of Jurkat cells that retained TCR expression but
failed to generate intracellular Ca2+ influx after TCR crosslinking, three independent Jurkat-
derived clones designated J.CaM1, J.CaM2, and J.CaM3 were obtained [32–34]. Analysis of
J.CaM1 (also called J.CaM1.6) cells revealed a defect in the expression of functional Lck
tyrosine kinase, as a consequence of a splicing defect of Exon 7, which gives a shorter (and
probably less stable) form of Lck. The introduction of the Lck cDNA in J.CaM1.6 cells
restored the ability of these cells to respond to TCR stimulation [35]. Several years after the
initial report, Arthur Weiss’s group found the signaling defect in J.CaM2 cells, revealing that
LAT transmembrane adaptor was not expressed, and that transfection of these cells with a
DNA coding for human LAT restored TCR-mediated PLC-γ1 activation, Ca2+ generation,
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and MAPK pathway activation [36]. Both cell lines have proved very useful in unraveling
the molecular mechanisms that govern the activation of T cells, and the role that several
domains or motifs of these proteins have in the TCR signaling cassette [8,9,35–38].
In this report, we characterize a new cell subline of J.CaM1.6 cells, originally described
as being defective in Lck expression, which additionally has lost the expression of LAT.
This new cell subline, that we have called J.CaM1.7, can re-express the LAT adaptor after
protein kinase C (PKC) activation with PMA, in the same way as J.CaM2 cells can re-express
LAT [39]. Contrary to J.CaM2, the LAT proximal promoter in J.CaM1.7 cells is similar
to that of Jurkat cells. Contrary to Lck-deficient J.CaM1.6 cells, lentiviral transfection of
J.CaM1.7 cells with a vector coding for human Lck is not enough to recover TCR-associated
intracellular signals, and transfection of both LAT and Lck is needed for a full recovery of
TCR signaling. Overall, our work shows that the new LAT negative J.CaM1.7 cell subline
could represent a new model to study LAT-Lck interaction, which seems to constitute an
essential early signaling event associated with the TCR/CD3 complex.
2. Materials and Methods
2.1. Antibodies and Reagents
Phorbol 12-myristate 13-acetate (PMA) and ionomycin (were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and were prepared in DMSO. Anti-LAT, anti-Lck, anti-PLC-γ,
and phospho-Erk antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany);
antibodies binding ZAP-70, phospho-ZAP-70-Tyr319, β-actin, phospho-PLC-γ1-Tyr783,
and phospho-LAT-Tyr171 were from Cell Signaling Technology (Danvers, MA, USA);
anti-Grb2 mAb was from Abcam (Cambridge, MA, USA); and anti-Erk mAb was from
BioLegend (San Diego, CA, USA). Stimulations were performed with the anti-human CD3
OKT3 monoclonal antibody (eBioscience, Thermo Fisher Scientific). Staining to assess
CD3 expression on the membrane was performed with OKT3 antibody conjugated to APC
(BioLegend, San Diego, CA, USA).
2.2. Cell Culture
The LAT-deficient J.CaM2 cell line was generously provided by Dr. Arthur Weiss, Uni-
versity of California, San Francisco (CA, USA). J.CaM1.6 cells were donated by Dr. Sancho,
Instituto de Parasitología y Biomedicina López Neyra, CSIC, Granada, Spain. All cells were
grown in complete RPMI 1640 medium supplemented with 10% FCS (both from Lonza,
Basel, Switzerland), and 2 mM L-glutamine at 37 ◦C in a humidified atmosphere containing
10% CO2.
2.3. Cloning and Lentiviral Transduction
LAT and Lck cDNA cloning was performed as previously described [40]. Coding
sequences in the plasmids were verified by sequencing and then subcloned in frame with
ZsGreen in the SIN lentiviral transfer plasmid pHR’SINcPPT-Blast through site-specific
recombination (Gateway LR Clonase, Invitrogen). Lentiviral supernatants were generated
as previously described [40] and used to induce expression of Lck, LAT, or the bi-cistronic
LAT-T2A-Lck cassette in J.CaM1.6, J.CaM1.7, J.CaM.2, or Jurkat cells. Blasticidin selection
(20 µg/mL) and/or Hygromycin (500 µg/mL) was applied to transduced cells after 72 h
of culture, and the expression of ZsGreen was analyzed using FACS analysis (CytoFLEX,
Beckman Coulter, Brea, CA, USA).
2.4. Cell Viability
Seventy-two hours after transduction with lentiviral plasmids of Jurkat, J.CaM2,
J.CaM1.6, and J.CaM1.7, cell viability was measured following APC Annexin V and Pro-
pidium Iodide staining protocol (BD, Pharmingen™), and analyzed by flow cytometry.
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2.5. RNA Isolation, cDNA Synthesis and Conventional PCR
Cytoplasmic RNA was purified using TRIzol™ LS Reagent (Invitrogen, ThermoFisher
Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. RNA was
reverse-transcribed using qScript™ cDNA Synthesis kit (QuantaBio, Beverly, MA, USA),
and used in qPCR and conventional PCRs with DreamTaq DNA Polymerase (Fermentas,
Thermo Fisher Scientific). Primer sequences for conventional human LAT conventional
PCR were: hLATFw3, 5′ gactgccaggctcctacg 3′; hLATRv3, 5′ ctgttggcaccatcagaatcc 3′.
Primer sequences for conventional human HRPT1 conventional PCR were: HRPT1Fw1, 5′
ggcgtcgtgattagtgatgatg 3′; HRPT1Rv1, 5′ gaatttatagccccccttgagc 3′.
2.6. Quantitative RT-PCR
The qRT-PCR assay was performed in three technical replicates per sample on a CFX
Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Amplifications
were carried out with PerFeCTa® SYBR® Green FastMix® (QuantaBio, Beverly, MA, USA).
Each qRT-PCR run included 5 ng of cDNA and the reaction conditions were 3 min at
95 ◦C followed by 40 cycles of 15 s at 95 ◦C, 35 s at 60 ◦C, and 10 s at 72 ◦C. To control for
the formation of primer dimers and unspecific amplification products, the melting curve
analysis was employed. The relative expression of LAT (amplified with Fw3/Rv4 primer
pair) was normalized to the expression of HPRT1. Each bar on the chart represents the
mean ± standard error of the mean (SEM). Statistics were performed with Microsoft Excel
using a two-tailed t-test. Levels of significance p < 0.001 are presented as *.
Primer sequences for human LAT qRT-PCR were hLATFw3, 5′ gactgccaggctcctacg 3′;
hLATRv4, 5′ ccgtgtgaggccgtttgaac 3′. Primer sequences for human HRPT1 qRT-PCR were
HRPT1Fw1, 5′ ggcgtcgtgattagtgatgatg 3′; HRPT1Rv2, 5′ caccctttccaaatcctcagc 3′.
2.7. Genomic DNA Purification and Sequencing
Genomic DNAs from Jurkat, J.CaM2, J.CaM1.6, and J.CaM1.7 cells were purified
using PureLink™ Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). The 2208 bp LAT gene fragment ranging from −916 to +1292 was amplified
with F1/R1 primer pair as previously described [39] with Phusion High-Fidelity DNA
Polymerase (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). PCR products were
sequenced with the next primers: F1, 5′ gggctcggtgctatttgtaa 3′; R1, 5′ gcctgggttgtgatagtcgt
3′; F2, 5′ ccacctggtgcctacctg 3′; R2, 5′ tgaggatgtgctgtcgtagg 3′; F3, 5′ agacttcccctgccacctt 3′;
R3, 5′ ttccccacacttaccaccat 3′.
2.8. PCR-RFLP
PCR fragments amplified with Taq polymerase (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) using F2/R2 primer pair from Jurkat, J.CaM2, J.CaM1.6 and J.CaM1.7
genomic DNA were digested with BamHI endonuclease to confirm the presence of het-
erozygous g.237 C > T mutation in J.CaM2. Digestion of the wild type 443 bp PCR product
generated 273 bp, 86 bp, and 84 bp fragments, whereas the mutant allele was digested into
273 bp and 170 bp fragments. F4/R4 primers were used to amplify 348 bp PCR product
from J.CaM2 and Jurkat cDNA and detect heterozygous c.167 C > T change in J.CaM2.
NlaIII digestion produced 362 bp, 101 bp, and 34 bp fragments from wild type DNA,
whereas mutant sequence was cut into 220 bp, 141 bp, 101 bp, and 34 bp products.
2.9. Preparation of Cell Lysates and Western Blotting
Lentivirally transduced J.CaM2 cells were starved in RPMI 1640 without FCS for 3 h be-
fore being stimulated with anti-CD3 mAb at 37 ◦C. Cells were then lysed at 2.0 × 107 cells/mL
in 2× Laemmli buffer, followed by incubation at 99 ◦C for 5 min and sonication. For Western
blotting, whole-cell lysates were separated by SDS-PAGE and transferred to PVDF membranes,
which were incubated with the indicated primary antibodies, followed by the appropriate
secondary antibody conjugated to IRDye 800 CW (Li-Cor, Lincoln, NE, USA) or horseradish
peroxidase (HRP). Reactive proteins were visualized using the Odyssey CLx Infrared Imaging
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System (Li-Cor) or by enhanced chemiluminescence (ECL) acquired in a ChemiDoc Touch
Imaging System (Bio-Rad Laboratories). For reprobing, PVDF membranes were incubated
for 10 min at room temperature with WB Stripping Solution (Nacalai Tesque, Kyoto, Japan),
followed by a TTBS wash.
2.10. Ca2+ Mobilization
Measurement of intracellular free Ca2+ was carried out using Indo-1 AM (acetoxymethyl)
(2 µM; Molecular Probes, Invitrogen) as previously described [40]. Calcium measurements
were performed using a Synergy MX Multi-Mode Reader (Biotek) at 37 ◦C. Cells were
excited by light at a wavelength of 340 nm, and the fluorescence emitted at 405 and 485 nm
was collected alternately per second. Calcium mobilization was evaluated by the ratio of
405/485 nm fluorescence signal.
3. Results
3.1. A New Subline of J.CaM1.6 Cells Which Do Not Express LAT
J.CaM1.6 cells grown in our laboratory under standard conditions were regularly
tested for Lck expression. As previously described, J.CaM1.6 cells do not express Lck
tyrosine kinase, as a consequence of a splicing defect of Exon 7, which gives a shorter
(and probably less stable) form of Lck, which can be seen with polyclonal antibodies or
monoclonal antibodies specific for the N-terminal part of the protein as a weaker and lower
molecular weight band [35] (Figure 1A). As a control of the protein load for the analysis of
Lck expression, we were using anti-LAT antibodies for the corresponding Western blots,
and we found in one of those Western blots that J.CaM1.6 cells in culture had lost LAT
expression (Figure 1A). Ponceau staining (not shown) and β-actin Western blot (Figure 1A)
showed equal protein load in all lanes, indicating that this new cell subline was specifically
negative for Lck and LAT expression. Furthermore, this new cell subline is positive for other
molecules belonging to the TCR/CD3 signaling cassette, such as ZAP-70, Grb2 (Figure 1A).
Quantification of three independent experiments shows no substantial differences in the
expression of Grb2 or ZAP-70 among the different cell lines, while quantification of LAT
and Lck shows a marked decrease of these proteins in the corresponding negative cell
lines (Supplementary Figure S1). We also analyzed CD3ε expression in these cells by flow
cytometry, showing that the new cells express comparable levels, both in percentage and
mean fluorescence intensity (MFI), to J.CaM1.6 and J.CaM2 cells, but lower than Jurkat
cells (Supplementary Figure S2). We called this new cell subline J.CaM1.7.
Next, to test if the failure in LAT expression of J.CaM1.7 cells was due to a post-
transcriptional defect, we isolated total RNA from them, and also from the parental
J.CaM1.6 cells. We used Jurkat cells as a positive control for LAT and Lck expression,
and J.CaM2 cells as a negative control of LAT. After reverse transcription of total RNAs,
cDNAs were obtained from J.CaM1.6, J.CaM1.7, Jurkat, and J.CaM2 cells, and amplified by
PCR with specific primers for LAT and β-tubulin cDNAs. As it can be seen in Figure 1B,
J.CaM1.7 cells were negative for both Lck and LAT, revealing that the failure in LAT ex-
pression was not due to a post-transcriptional defect. We also analyzed LAT expression
by quantitative RT-PCR in the new J.CaM1.7 cell line. As it can be seen in Figure 1C, the
LAT mRNA level of J.CaM1.6 cells was about 50% compared to Jurkat cells. It has been
reported that this expression level is enough to reestablish intracellular signaling coupled
to the TCR/CD3 complex [35], and fits well with the lack of phenotype of heterozygous
LAT+/− mice [41]. However, J.CaM1.7 cells showed 12% of LAT expression compared to
Jurkat cells (Figure 1C). Although this level of expression is not as low as the one shown by
J.CaM2 cells (about 2% with regard to Jurkat cells), this reduced expression is probably the
reason that prevents the detection of LAT protein by Western blotting.
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Figure 1. J.CaM1.7 cells are double negative for LAT and Lck expression. (A) J.CaM1.7 cells derived
from J.CaM1.6 cells were analyzed for LAT, Lck, and β-actin expression by Western blot. Lysates
obtained from 106 Jurkat, J.CaM2 (LAT deficient), J.CaM1.6 (Lck deficient), and J.CaM1.7 cells were
analyzed by Western blot with the indicated specific antibodies. (B) RT–PCR analysis of Jurkat,
J.CaM2, J.CaM1.6, and J.CaM1.7 cells with specific primers for LAT and HPRT1. For each cell line, a
negative control has been included in which RNA was treated without reverse transcriptase. (C) LAT
relative mRNA levels determined by qPCR analysis in the indicated cell lines and normalized against
HPRT1. Values are displayed as m ans ± s.d. of three independent biological replicates. Asterisks (*)
represent statistical significance (p < 0.001).
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3.2. Long-Term Culture of J.CaM1.6 Cells Does Not Affect LAT Expression
Lck-deficient J.CaM1.6 cells were initially obtained by an approach in which Jurkat
cells were mutagenized with ethyl methanesulfonate and were subsequently grown in
the presence of PHA, which arrests cell proliferation [32]. Jurkat cells still expressing
the TCR/CD3 complex and resistant to the growth-inhibitory effect of PHA might also
be deficient in transmembrane signaling, and indeed authors included in their selection
protocol the inability to mobilize calcium in response to anti-TCR antibody crosslinking [32].
Later on, the same group discovered that J.CaM1.6 cells were defective in the expression of
functional Lck tyrosine kinase, and this defect was caused in part by a splicing defect [35].
Interestingly, transfection of a cDNA coding for Lck restored the ability of the J.CaM1.6
cells to respond to TCR stimulation [35]. Therefore, given the stochastic nature of this
cell line, and the serendipity of our discovery of a new cell line double deficient in Lck
and LAT expression, we wondered if J.CaM1.6 cells were prone to lose LAT expression
under long periods in culture. Consequently, we kept J.CaM1.6 cells in culture for more
than 6 months, and cell lysates were obtained periodically. As can be seen in Figure 2A,
continuous culture of J.CaM1.6 cells at 37 ◦C for 28 weeks did not decrease LAT expression,
and even LAT levels increased from week 20. We also analyzed the expression levels of
other molecules belonging to the signaling cassette. As shown in Supplementary Figure S3,
no substantial changes maintained over time were observed in the expression of ZAP-70,
PLC-γ, or SLP-76. From this result, we can conclude that our cells are the product of a
random event which precluded LAT expression.
3.3. Protein Kinase C Activation Recuperates LAT Expression in J.CaM1.7 Cells
We have previously described that J.CaM2 cells are able to re-express LAT after
activation of protein kinase C with phorbol 12-myristate 13-acetate (PMA) [39]. Indeed,
stimulation of J.CaM2 cells with PMA for 24 h induced the expression of LAT (Figure 2B,C).
In J.CaM1.6 cells (Lck deficient but LAT positive), the same PMA treatment produced an
increase in the basal expression of LAT (Figure 2B,C), similar to what has been described
for Jurkat cells [39]. Interestingly, similar to the LAT deficient J.CaM2 cell line, J.CaM1.7
cells recovered LAT expression after 24 h of treatment with 20 ng/mL of PMA. Calcium
ionophore ionomycin abolished PMA-induced LAT expression in J.CaM1.7 cells, as well as
in J.CaM2 cells, and is consistent with the previously observed negative effect of calcium
signaling on the activation-induced LAT expression in Jurkat cells [42]. Thus, these results
show that although LAT basal expression is strongly repressed in J.CaM1.7 cells, PKC
activation stimulates LAT expression.
3.4. Analysis of the LAT Proximal Promoter Reveals No Changes in J.CaM1.7 Cells
As we previously did to find changes in the LAT genomic sequence of J.CaM2 cells [39],
we PCR-amplified a fragment of genomic DNA obtained from J.CaM1.7 cells, comprising a
region of 2208 bp surrounding the translational start site (Figure 3A, primers F1 and R1).
Sequencing of this genomic region in J.CaM2 cells previously showed two heterozygous
mutations, absent in Jurkat cells, and affecting different alleles. Both mutations were C
to T mutations, the first one located in intron 1 at gene position 237, and the second one
located in exon 4 at position 167, causing the LAT threonine 56 residue to be substituted by
a methionine (Figure 3A). However, sequencing of the same region amplified from genomic
DNA obtained from J.CaM1.7 cells showed no differences with the published sequence of
Jurkat E6 cells (Figure 3A). The sequence of the genomic DNA obtained from J.CaM1.6 cells
was also analyzed, which showed that the sequence was identical in this region to that of
Jurkat cells (data not shown). The absence of those mutations was additionally confirmed
by PCR–restriction fragment length polymorphism (RFLP) performed on genomic DNA
from J.CaM1.7, J.CaM1.6, J.CaM2, and Jurkat cells as a control (Figure 3B).
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Figure 2. Stability and induction of LAT expression in J.CaM1.6 and J.CaM1.7 cells. (A) J.CaM1.6
cells were grown at 37 ◦C and 5% CO2 continuously after thawing for the indicated weeks, an then
cell lysates were obtained and analyzed for LAT, Lck, and β-actin expression by Western blot. Lysates
obtained from Jurkat and J.CaM2 were incorporated as positive and negative controls. (B) J.CaM2,
J.CaM1.6, and J.CaM1.7 cells were unstimulated or PMA treated (20 ng/mL) in the absence or
presence of ionomycin (Iono; 3 µM). Whole-cell lysates were prepared 24 h post-stimulation and
immunoblotted with antibodies specific for LAT, Lck, and Erk. (C) LAT protein relative expression
determined by densitometric quantification of Western blot in subfigure (B) normalized against Erk
expression. Data in subfigures (B,C) are representative of three biological replicates. NT, not treated;
P, PMA; I, ionomycin; P + I, PMA + ionomycin.
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Figure 3. Sequence analysis in LAT gene of J.CaM1.7 cells (A) Schematic representation of the human
genomic region of LAT gene and histograms showing homozygous wild type “C” nucleotides in
intron 1 (position g.237) and exon 4 (position c.167) in J.CaM1.7 cells. As a control, the same sequence
analysis was performed in J.CaM2 cells, and heterozygous variants C > T in positions g.237 and c167
are shown. F1 and R1: primers used to amplify genomic DNA to be sequenced. F2, F3, R2 and R3:
primers used for sequencing. (B) Mutations in J.CaM2 cells were confirmed by the digestion of PCR
product 2 (amplified with primers F2 and R2 from genomic DNA) with BamHI endonuclease (for the
mutation in intron 1) and by the digestion of PCR product 3 (amplified with primers F3 and R3) with
NlaIII. As it can be observed, only J.CaM2 cells presented both mutations, and cells J.CaM1.6 and
J.CaM1.7 presented the same genotype as Jurkat cells.
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3.5. Effect of LAT Expression on Cell Viability
Although kinases are typically associated with a protective function against apoptosis,
it has been shown that the tyrosine kinase Lck is associated with apoptosis induced by
ionizing radiation or cytotoxic drugs [43,44]. J.CaM1.6 cells, deficient in Lck expression,
show decreased apoptosis in response to ionizing radiation when compared to Jurkat
cells or Lck-transfected J.CaM1.6 cells, although similar cell death rates are observed after
Fas engagement [43]. Similar results were obtained when the apoptosis in response to
anticancer drugs was analyzed, with J.CaM1.6 cells showing strongly diminished cell death
rates after treatment with fluorouracil, doxorubicin, or paclitaxel [44]. Therefore, it was
of interest to analyze if LAT expression affects cell viability in J.CaM1.6 and J.CaM1.7
cells. To do so, we generated two lentiviral plasmids in order to reintroduce Lck or LAT
and Lck (Figure 4A). To distinguish between the endogenous and the transfected forms,
we introduced in the coding region of LAT an Avi-Tag, which would allow us to detect
the transfected form by means of a specific monoclonal antibody, and also because this
construct generated a form of LAT of greater size than the of endogenous one (Figure 4A).
Similarly, a construct was generated including the coding region of human Lck and a 6-His
tag at the C-terminal end. To express at the same time LAT and Lck, a lentiviral vector was
generated with a T2A sequence between the coding regions of LAT and Lck (Figure 4A).
Several viruses use 2A peptides to mediate protein cleavage, and 2A motifs can be used to
generate multi-cistronic expression vectors [45]. We introduced a T2A sequence because
this sequence has already been used to successfully express CD3-ε, CD3-γ, and CD3-δ. Both
plasmids also contained an IRES sequence followed by the coding region of the fluorescent
protein ZsGreen, which would allow us to verify the level of lentivirally transduced cells
by flow cytometry.
To check whether these constructs allowed the expression of these proteins, Hek Lenti-
X cells were transfected with these plasmids, and the level of transfection and expression
of LAT and Lck was analyzed. As can be seen in Figure 4B, both plasmids transfected HEK
cells, with the efficiency exceeding 95% of cells expressing ZsGreen. Moreover, HEK cells
transfected with the plasmid containing the coding region of Lck allowed the expression
of this tyrosine kinase, while cells transfected with the plasmid coding for LAT and Lck
expressed both proteins (Figure 4C). Of note, the LAT immunoblot shows that Hek cells
transfected with the vector coding for LAT and Lck with a T2A sequence also expressed
the LAT/Lck fusion protein (Figure 4C, black arrow), although the amount of this protein
present was significantly less than that of the individual proteins.
Next, we lentivirally transduced J.CaM1.6 and J.CaM1.7 cells (Lck-deficient and double
LAT-Lck-deficient, respectively) with the corresponding lentiviral expression plasmids for
Lck or LAT + Lck. Although the bi-cistronic plasmid did not allow expression of LAT and
Lck for long periods, the transient expression of both proteins did allow us to evaluate
the effect on cell viability, with similar levels of transfection in both types of cells with the
lentiviral plasmid coding for Lck or the one coding for LAT and Lck (Figure 5A). Jurkat
cells and LAT deficient J.CaM2 cells were also lentivirally transduced with both plasmids
as controls. Seventy-two hours after lentiviral transduction cell viability was assessed by
means of Annexin V and Propidium Iodide staining, and no differences could be detected
between Lck-deficient J.CaM1.6 cells and the double-deficient LAT-Lck J.CaM1.7 cells
(Figure 5B). Lentiviral transduction of Lck or LAT + Lck induced a modest decrease in cell
viability, which was similar in J.CaM1.6 and J.CaM1.7 cells, and was also similar to what
occurred in J.CaM2 cells (Figure 5B). Lentiviral transduction of Jurkat cells did not affect
their viability. Therefore, the loss of LAT expression that has occurred in J.CaM1.7 cells
does not seem to affect their viability, when compared to J.CaM1.6 cells, nor when LAT or
LAT + Lck are reintroduced in both cell types.
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with the indicated plasmids. Lysates obtained from 106 cells were analyzed by Western blot with 
the indicated specific antibodies. Arrow on the right indicates the LAT-Lck fusion protein. 
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(A) Schematic representation of the coding regions included in the lentiviral plasmids generated
for the expression of Lck or LAT plus Lck. The T2A sequence between LAT and Lck is indicated
in red. ZsGreen reporter is located after the Lck-6His fusion gene and an IRES sequence in both
plasmids. (B) 72 h after the transfection of the HEK Lenti-X packaging cell line, the expression of the
reporter ZsGreen was determined by flow cytometry. Numbers indicate the percentage of ZsGreen
positive cells (black line). Gray line corresponds to untransfected HEK Lenti-X cells. (C) LAT and
Lck expression was analyzed in Jurkat or HEK Lenti-X untransfected or tran f cted with t e
indicated plasmids. Lysates btained from 106 cells were an lyzed by Western blot with the indicated
specific antibodies. Arrow on the right indicates the LAT-Lck fusion protein.
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non-transduced cells. (B) Viability of Jurkat, J.CaM2, J.CaM1.6, or J.CaM1.7 cells was analyzed 72 h 
after lentiviral transduction with the indicated plasmids using staining with APC labeled annexin 
V and propidium iodide (PI) and analyzed by FACS. Cell viability was estimated as the percent-
age of annexin V and PI negative cells. The values presented are the mean values of six experi-
ments. Bars represent the standard error. 
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Figure 5. The expression of LAT or Lck does not affect the viability of J.CaM1.6 or J.CaM1.7 cells.
(A) 72 h after lentiviral transduction of J.CaM1.6 or J.CaM1.7 cells with plasmids coding for Lck
(black line) or LAT + Lck (red line) the expression of the reporter ZsGreen was determined by flow
cytometry. Numbers indicate the percentage of ZsGreen positive cells. Gray line corresponds to
non-transduced cells. (B) Viability of Jurkat, J.CaM2, J.CaM1.6, or J.CaM1.7 cells was analyzed 72 h
after lentiviral transduction with the indicated plasmids using staining with APC l beled ann xin V
nd propidium iodi e (PI) and analyzed by FACS. Cell viability was estimated a the percentage of
annexin V and PI negative cells. The values presented are the mean values of six experiments. Bars
represent the standard error.
3.6. Simultaneous Expression of LAT and Lck Is Needed to Recover TCR Signaling in
J.CaM1.7 Cells
As commented above, long-term culture of cells transduced with the bi-cistronic
lentiviral vector for LAT + Lck with the T2A sequence was not possible, as after one week
of culture the proliferation of these cells was blocked (both J.CaM1.6 and J.CaM1.7 cells),
and it was not possible to perform further experiments (data not shown). As there were
no differences in this response between both cell types, the underlying reason may be the
large size of the lentiviral vector used to simultaneously express LAT and Lck. Therefore,
we generated a new lentiviral vector for a fusion protein containing the coding region of
human LAT and a 6-His tag at its C-terminal end (Figure 6A). Similar to the Lck lentiviral
plasmid, this plasmid also contained an IRES sequence followed by the coding region of
the fluorescent protein mCherry which would allow us to verify the level of lentivirally
transduced cells by flow cytometry. We lentivirally transduced J.CaM1.6 and J.CaM1.7 cells
with the expression plasmid for Lck or with a combination of the LAT and Lck expression
plasmids. We also transduced Jurkat and J.CaM2 cells as controls. As can be seen in
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Figure 6B, transduction of J.CaM1.6 and J.CaM1.7 cells with the Lck plasmid reconstituted
the expression of this tyrosine kinase, and double transduction with LAT and Lck plasmids
recovered LAT and Lck expression in J.CaM1.7 cells.
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(1.7) cells with plasmids coding for Lck and LAT. Immunoblots were done with the indicated anti-
bodies. Anti-β actin immunoblot in the lower panel was performed with the same cell lysates to 
show equal protein loading. (C) J.CaM1.6 cells (left panel) and J.CaM1.7 cells non-transduced 
(green line) or lentivirally transduced with plasmids coding for Lck (red line) or with the two plas-
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Figure 6. Lentiviral transduction of LAT and Lck in J.CaM1.6 and J.CaM1.7 cells and calcium analysis.
(A) Schematic re tion of the coding regions included in the lentiviral plasmids generated for
the expression of Lck and LAT. ZsGreen or Cherry reporters are located after an IRES sequence,
placed downstream of Lck-6His or LAT-6His, respectively. (B) LAT and Lck expression was analyzed
after lentiviral transduction of Jurkat (Jkt), J.CaM2 (J2), J.CaM1.6 (1.6), and J.CaM1.7 (1.7) cells with
plasmids cod g for Lck and LAT. Immunoblots were done wit the indicated antibodies. Anti-β
actin immunoblot in the lower panel was performed with the same cell lysates to show equal protein
loading. (C) J.CaM1.6 cells (left panel) and J.CaM1.7 cells non-transduced (green line) or lentivirally
transduced with plasmids coding for Lck (red line) or with the two plasmids coding for LAT and
Lck t were loaded with Indo-1AM and stimulated with OKT3 mAb (1 µg/mL) at the indicated times
(black arrows). The intracellular Ca2+ concentration was determined at 37 ◦C through the change in
Indo-1AM fluorescence. The graphics represent the average of 9 experiments.
Next, we analyzed calcium responses after anti-CD3 stimulation. Indo-1AM-labeled
cells were stimulated with 1 µg/mL of OKT3 mAb and Ca2+ influx was analyzed. As
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previously reported [35], Lck-deficient J.CaM1.6 cells were unable to increase intracellular
Ca2+ levels in response to CD3 stimulation, but lentiviral transfection of Lck or the double
transfection of LAT and Lck recovered calcium signaling (Figure 6C, left panel). However,
the reintroduction of Lck in J.CaM1.7 cells was not sufficient to recover calcium signals
after stimulation with anti-CD3 mAb, while the double transfection with LAT and Lck
recovered the calcium increase in a similar way as it happened in J.CaM1.6 cells (Figure 6C,
right panel).
Then, to check other intracellular signals associated with the TCR/CD3 complex, we
performed a series of experiments in which the different cell types were stimulated with
OKT3 during different periods, and the cell lysates were analyzed for the phosphorylation
of PLC-γ, Erk and LAT-Y171 using Western blot. As it can be seen in Figure 7, both
non-transduced J.CaM1.6 and J.CaM1.7 cells did not show phosphorylation of PLC-γ
after CD3 stimulation. As expected, re-expression of Lck was enough to recover ZAP-
70 phosphorylation in both J.CaM1.6 and J.CaM1.7 cells (Figure 7). Reintroduction of
Lck in J.CaM1.6 cells was sufficient to restore PLC-γ activation, but in J.CaM1.7 cells
simultaneous transfection with the plasmids coding for LAT and Lck was required for the
recovery of the phosphorylation of this kinase (Figure 7 and Supplementary Figure S4). We
also analyzed Erk phosphorylation in Lck and LAT + Lck transduced cells. As it can be
observed in Figure 7, the transfection of Lck was enough to recuperate Erk phosphorylation
upon CD3 stimulation, and the reintroduction of LAT in J.CaM1.7 cells was not necessary
for Erk activation. Next, to confirm that LAT was properly transducing intracellular
signals coming from the TCR/CD3 complex, we analyzed LAT phosphorylation in non-
transduced and lentivirally transduced J.CaM1.6 and J.CaM1.7 cells. As can be seen in
Figure 7, the reintroduction of Lck expression in J.CaM1.6 cells was sufficient to recover
the phosphorylation of LAT tyrosine 171, and the double transfection with Lck and LAT
plasmids generated a double band of phosphorylated LAT, which corresponded to the
endogenous and transfected forms. As expected, only double transfection of J.CaM1.7
cells with LAT and Lck allowed the phosphorylation of LAT tyrosine 171 (Figure 7 and
Supplementary Figure S4).
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lular signals associated with the TCR/CD3 complex in J.CaM1.7 cells. Immunoblot analysis of 
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with vectors coding for Lck or LAT and Lck, as depicted. Whole-cell lysates were obtained after 
stimulation with an anti-CD3 antibody (OKT3, 1 μg/mL) for the indicated incubation times. β-
actin immunoblots were performed to show equal protein expression. Images are representative of 
at least three experiments. 
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the use of tumor cell lines. One of the most popular is the human leukemic Jurkat cell line 
(for a review see in [26]). Jurkat cells allowed the discovery of essential molecular events 
in T cell biology, such as the need of CD3 polypeptides for the expression of the αβ-TCR 
heterodimer at the cell surface [46], that TCR stimulation triggers a fast increase in Ca2+ 
concentration [29] or the relevance of the ζ-chain to couple the TCR to intracellular signal 
transduction mechanisms [47]. Of special relevance has been the use of genetically altered 
Jurkat T cell lines generated by genome-wide mutagenesis approaches, which allowed to 
prove the essential role of the tyrosine kinase Lck and the transmembrane adaptor LAT 
for the transduction of intracellular signals coming from the TCR/CD3 complex [35,36]. 
J.CaM1.6 and J.CaM2 cell lines have been extremely useful to establish the role of some 
domains and consensus motifs in Lck or LAT for T cell activation. In this work, we present 
a new cell line doubly deficient in Lck and LAT expression, which increases the array of 
T cell lines for the combined analysis of the molecular events taking place after TCR en-
gagement. As this new cell line stems from a random event from the continuous culture 
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Figure 7. Simultaneous expression of LAT and Lck is necessary for the restoration of the intracellular
signals associated with the TCR/CD3 complex in J.CaM1.7 cells. Immunoblot analysis of J.CaM1.6
(left panels) and J.CaM1.7 cells (right panels), non-transduced, or lentivirally transduced with vectors
coding for Lck or LAT and Lck, as depicted. Whole-cell lysates were obtained after stimulation with
an anti-CD3 antibody (OKT3, 1 µg/mL) for the indicated incubation times. β-actin immunoblots were
performed to show equal protein expression. Images are representative of at least three experiments.
Cells 2021, 10, 343 15 of 20
4. Discussion
T lymphocytes are central players in immune responses, and the time-regulated
activation of these cells is crucial to prevent immune-based diseases. After recognition of a
specific antigen by the TCR receptor, T lymphocytes trigger an intracellular signal cascade
that leads to the activation, proliferation, and differentiation of T cells into different types
of effector cells [5]. Many of the key components of the TCR signaling cassette have now
been identified and characterized, and very often these advances have been made through
the use of tumor cell lines. One of the most popular is the human leukemic Jurkat cell line
(for a review see in [26]). Jurkat cells allowed the discovery of essential molecular events
in T cell biology, such as the need of CD3 polypeptides for the expression of the αβ-TCR
heterodimer at the cell surface [46], that TCR stimulation triggers a fast increase in Ca2+
concentration [29] or the relevance of the ζ-chain to couple the TCR to intracellular signal
transduction mechanisms [47]. Of special relevance has been the use of genetically altered
Jurkat T cell lines generated by genome-wide mutagenesis approaches, which allowed to
prove the essential role of the tyrosine kinase Lck and the transmembrane adaptor LAT
for the transduction of intracellular signals coming from the TCR/CD3 complex [35,36].
J.CaM1.6 and J.CaM2 cell lines have been extremely useful to establish the role of some
domains and consensus motifs in Lck or LAT for T cell activation. In this work, we present
a new cell line doubly deficient in Lck and LAT expression, which increases the array
of T cell lines for the combined analysis of the molecular events taking place after TCR
engagement. As this new cell line stems from a random event from the continuous culture
of J.CaM1.6 cells, we have named it J.CaM1.7.
We have found the new cell line defective in LAT expression during regular Western
blotting verifications of Lck expression by J.CaM1.6 cells in culture, and anti-LAT antibodies
were used as loading controls. We have shown that J.CaM1.7 cells do not express LAT
protein and that LAT mRNA is strongly decreased. Interestingly, analysis of LAT expression
in J.CaM1.6 cells maintained in culture for 6 months did not reveal a new loss of LAT
expression in J.CaM1.6 cells, suggesting that our discovery was not a likely event. This
was of interest given the potential implications of LAT-mediated intracellular signaling for
TCR/CD3 complex expression at the cell surface. Although we did not find substantial
differences in CD3ε expression between J.CaM1.6 and J.CaM1.7 cells, it has been shown that
mouse T cells expressing a LAT mutant in which tyrosine 136 (mouse ortholog of human
tyrosine 132) has been mutated to phenylalanine and which has a decreased signaling
ability show reduced levels of TCR/CD3 complex [48,49]. Moreover, primary mouse CD4+
T lymphocytes deprived of LAT express lower levels of TCR [50]. In this context, it has been
shown that constitutive signals transduced through LAT are needed to maintain surface
expression of the TCR/CD3 complex in Jurkat cells [51]. On the other hand, LAT expression
is transiently upregulated upon TCR engagement, although intracellular signals leading to
enhanced LAT transcription are not fully understood [39,52,53]. The intensification of LAT
expression depends on PKC activity as inhibition of this kinase blocks the increase produced
by TCR crosslinking or PMA treatment in Jurkat cells [52]. Regarding the regulation of
basal LAT expression, it has been demonstrated that LAT has a 5′ proximal promoter that
spans approximately 800 bp upstream of the translation start site and contains binding
sites for Ets, Runx Sp1, and Sp3 transcription factors [54,55]. Interestingly, Sp1 and Sp3
knockdown or their pharmacological inhibition with mithramycin A downmodulate LAT
promoter activity [39].
We have previously shown that J.CaM2 LAT-deficient cells have no sequence difference
in the entire LAT promoter, and only two point mutations have been found in the gene
body [39]. One of these mutations is located in intron 1 at gene position 237, and the
second one is inside exon 4 at position 167. We have found no differences in the genomic
sequence of the LAT gene in J.CaM1.7 cells, neither in the promoter nor the gene body,
and other cis-elements and/or transcription factors may have been affected in J.CaM1.7
cells leading to deficient LAT expression. In this context, it is intriguing to speculate
that the very same master regulator of basal LAT expression has been affected both in
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J.CaM1.7 and J.CaM2 cell lines. If so, future work using next-generation RNA sequencing
and/or whole genome sequencing may clarify this issue. This knowledge would allow
the manipulation of basal LAT expression for medical purposes (i.e., autoimmune or
lymphoproliferative diseases). As the expression of LAT in J.CaM1.6 cells is decreased
with respect to Jurkat cells, it is conceivable that TCR-dependent intracellular signals favor
basal LAT expression. In this setting, in the same way, that LAT has a role in keeping the
expression levels of the TCR complex, reciprocally, the TCR-mediated signals are needed
to maintaining LAT expression. We have also demonstrated that PKC activation by PMA
treatment induces LAT re-expression in J.CaM1.7 cells, in the same way as it happens in
J.CaM2 cells, with ionomycin blocking the effect induced by PMA, supporting the finely
regulated mechanisms controlling both basal and activation-mediated LAT transcription.
We have also analyzed the survival rates of J.CaM1.6 and J.CaM1.7 cells before and
after lentiviral transfection with Lck or LAT and Lck DNAs. There is some debate on the role
Lck kinase plays in T cell survival and apoptosis. Although the role of Lck in transducing
activation signals leading to proliferation and survival is broadly accepted, a critical role of
Lck in activation-induced cell death (AICD) by weak agonists without ZAP-70 and LAT
phosphorylation has been postulated as well [56]. In that report, pharmacological inhibition
of Lck or genetic abrogation of Lck expression prevented AICD of T cells. Moreover, it
has been shown that null mutations in Lck abrogate Fas signaling in T cells [57]. Lck is
also needed for the apoptosis induction of endothelial cells [58]. On the other side, it has
been recently shown that Lck is aberrantly expressed in T-acute lymphoblastic leukemia
(T-ALL) patients displaying resistance to glucocorticoid (GC) treatment, and specific Lck
inhibition or LCK gene silencing strikingly increases GC-induced cell death of tumor
cells [59]. However, we have found no differences in basal survival rates between J.CaM1.6
(Lck deficient) and J.CaM1.7 (LAT and Lck deficient). More work is needed to clarify
whether LAT is needed to transduce proapoptotic or survival signals, and this new cell line
constitutes an interesting tool to address some of these issues.
The main interest that the new J.CaM1.7 cell line may have is for the study of intra-
cellular signaling associated with the TCR. In this context, we have demonstrated that,
contrary to J.CaM1.6 cells, the reintroduction of Lck expression in J.CaM1.7 cells is not
enough to recover intracellular signals, such as Ca2+ increase or PLC-γ phosphorylation.
Although the new J.CaM1.7 cells express significantly higher LAT levels than J.CaM2, this
amount of LAT is not sufficient to transduce activation intracellular signals from the TCR.
Both LAT and Lck had to be transfected to recuperate activation signals triggered by the
TCR/CD3 complex. Therefore, the J.CaM1.7 cell line represents an interesting model to
address the relationship between Lck and LAT. Although it has been demonstrated that
ZAP-70 is the tyrosine kinase phosphorylating LAT, both molecules have a functional
link with important functional consequences. Weiss and coworkers have shown that a
proline-rich motif of LAT binds to the SH3 domain of Lck, bridging ZAP-70 to LAT and
so promoting LAT phosphorylation [22]. Our group has also shown that a negatively
charged stretch of amino acids in LAT is involved in LAT-Lck interaction and that such
interaction is needed to fine-tune intracellular signals triggered by the TCR [25]. Therefore,
it is conceivable that Lck has a role in negative regulation of TCR signaling, and J.CaM1.7
could be of help to address the relevance of LAT consensus motifs and Lck domains in this
negative feedback loop.
In our analysis of TCR signaling performed in lentivirally transduced J.CaM1.6 and
J.CaM1.7 cells, we have not observed significant differences between Ca2+ responses in
J.CaM1.6 cells transfected with Lck or LAT + Lck, which suggests that a threshold level
of LAT expression is enough to activate biological responses in T cells. This is in line
with the phenotype of heterozygous mice for LAT knockout or several strains of LAT
knockins [41,48,49,60,61]. As previously commented, J.CaM1.7 cells need the reintroduc-
tion of both Lck and LAT to recover TCR signaling. However, we have observed that
Erk phosphorylation is similar in the absence of LAT, and the lentiviral transfection of
LAT had no substantial effect on Erk phosphorylation. This is controversial because it
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has been previously reported that LAT deficiency in J.CaM2 cells was needed for Erk
phosphorylation [8,9,36]. Using a mouse genetic model in which LAT molecules were
expressed in the thymus to permit normal thymic selection and proper CD4+ T cell de-
velopment, Malissen and coworkers were able, using a Cre recombinase-based system, to
generate CD4+ T lymphocytes deprived of LAT [50]. In this system, LAT-deficient CD4+ T
lymphocytes cells showed no ERK 1 and 2 activation after TCR engagement. Moreover,
a human immunodeficiency has been described in which a loss-of-function mutation of
LAT generated strongly reduced numbers of T cells, with abolished Erk signaling [62].
However, other reports support our observation of LAT-independent Erk activation, as
mice harboring a mutation of LAT that prevents PLC-γ binding and activation (LAT-Y136F)
show normal Erk activation [49]. Besides, Samelson and coworkers have demonstrated
a LAT-independent pathway by which Erk can be activated after CD3 stimulation [63].
Our results support such a LAT-independent Erk activation pathway, which could explain
the lymphoproliferative disease observed in LAT-Y136F knock-in mice as the result of
imbalanced Erk- and Ca2+-dependent signals. In summary, we present here the initial
characterization of a new cell line, J.CaM1.7, double deficient in LAT, and Lck expression.
This cell line may constitute a new tool to untangle molecular events related to the TCR
signaling cassette and biology of T cells. Through the lentiviral transfection of J.CaM2 cells,
we have recently shown that a mutation of LAT glycine 131 to aspartate increases IL-2
production in response to CD3/CD28 engagement [64]. The new J.CaM1.7 cells may be
useful to confirm these data and verify the role of Lck domains or motifs in this behavior.
Supplementary Materials: The following are available online at https://www.mdpi.com/2073-4
409/10/2/343/s1. Supplementary Figure S1 Quantification of protein expression levels. Diagrams
representing quantification of immunoblots for LAT, Lck, ZAP-70, Grb2, and β-actin expression by
Jurkat, J.CaM2, J.CaM1.6, and J.CaM1.7 cells in three independent experiments. Columns represent
the mean value of the relative quantities of each protein, and the bars the standard error. Numbers
at the left of each panel represent relative units. Supplementary Figure S2. Expression of CD3ε.
Histograms of CD3ε expression in Jurkat, J.CaM2, J.CaM1.6, and J.CaM1.7 cells. Numbers in
the histograms represent the percentage of positive cells and mean fluorescence intensity (MFI).
Supplementary Figure S3. Expression of some proteins in the TCR signaling cassette. J.CaM1.6
cells grown at 37 ◦C and 5% CO2 continuously after thawing for the indicated weeks, and then cell
lysates were obtained and analyzed for ZAP-70, PLC-γ, and SLP-76. Lysates obtained from Jurkat
and J.CaM2 were incorporated as controls. Supplementary Figure S4. Quantification of intracellular
signals in J.CaM1.6 and J.CaM1.7 cells. J.CaM1.6 cells and J.CaM1.7 cells, non-transduced (Unt.),
or lentivirally transduced with vectors coding for Lck or LAT and Lck were stimulated with anti-
CD3 antibody (OKT3, 1 µg/mL) for the indicated incubation times. After immunoblots with the
corresponding monoclonal antibodies (see Figure 7), densitometric quantifications were performed
(n = 3), and phosphorylation levels were normalized to total protein expression. Brackets represent
the standard error.
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